| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 2
| Issue : 2 | Page : 45-48 |
|
|
Efficacy of iron isomaltoside among anemic females of Bundelkhand region: An interventional study
Anupma Upadhyay1, Syed Esam Mahmood2, Meena Saxena1, Kanchan Singh1
1 Department of Obstetrics and Gynaecology, Government Medical College, Banda, Uttar Pradesh, India
2 Department of Community Medicine, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh, India
Correspondence Address:
Dr. Syed Esam Mahmood
Department of Community Medicine, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijas.ijas_4_18
|
|
|
Introduction: More than a quarter of the world's population is anemic with about one half of the burden from iron deficiency. The prevention and treatment of iron deficiency is a major public health goal especially in women in low-income countries. Challenges in the treatment of iron deficiency include a selection of an iron replacement product that can be given as high-dose intravenous (IV) infusion in single visit with good safety profile. In this pilot study, a new IV therapeutic agent iron isomaltoside 1000 with above-desired properties was investigated to establish its efficacy in the treatment of iron deficiency anemia (IDA).
Material and Methods: This 3 months' prospective interventional hospital-based study was conducted on 42 nonpregnant women with moderate-to-severe anemia attending obstetrics and Gynecology Department at Government Medical College Banda in Bundelkhand region. Pre- and post-hemoglobin (Hb) estimation after 3 weeks of a single shot of iron isomaltoside 1000 IV infusion was done. A rise in Hb of 2 g/dl or more at 21 days was considered a satisfactory response. SPSS software 17.0 version was used for data analysis.
Results: Mean preinfusion Hb was found to be 7.139 g/dl and mean postinfusion Hb was found to be 10.088 g/dl. Thus, a rise of 2.949 g/dl in mean Hb after 3 weeks was recorded after a single infusion of iron isomaltoside among the anemic females.
Conclusion: Iron isomaltoside has demonstrated robust efficacy in patients suffering from IDA due to different etiologies. The wide dosing range allows iron correction in a single visit with minimal risk of anaphylaxis and is thus cost-effective for health-care system.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
